CA2590781A1 - Diagnostic de maladies neurodegeneratives - Google Patents
Diagnostic de maladies neurodegeneratives Download PDFInfo
- Publication number
- CA2590781A1 CA2590781A1 CA002590781A CA2590781A CA2590781A1 CA 2590781 A1 CA2590781 A1 CA 2590781A1 CA 002590781 A CA002590781 A CA 002590781A CA 2590781 A CA2590781 A CA 2590781A CA 2590781 A1 CA2590781 A1 CA 2590781A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- precursor
- adv
- sample
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003745 diagnosis Methods 0.000 title claims abstract description 22
- 208000015122 neurodegenerative disease Diseases 0.000 title description 4
- 230000004770 neurodegeneration Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 108
- 239000002243 precursor Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 44
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 40
- 102000003780 Clusterin Human genes 0.000 claims abstract description 14
- 108090000197 Clusterin Proteins 0.000 claims abstract description 14
- 102000007469 Actins Human genes 0.000 claims abstract description 12
- 108010085238 Actins Proteins 0.000 claims abstract description 11
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims abstract description 11
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims abstract description 11
- 230000003247 decreasing effect Effects 0.000 claims description 59
- 239000003550 marker Substances 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 230000000926 neurological effect Effects 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 5
- 238000000159 protein binding assay Methods 0.000 claims description 4
- 210000005013 brain tissue Anatomy 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- 101710150593 Protein beta Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 5
- 108010056301 Apolipoprotein C-III Proteins 0.000 abstract description 4
- 102000030169 Apolipoprotein C-III Human genes 0.000 abstract description 4
- 239000002753 trypsin inhibitor Substances 0.000 abstract description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract description 3
- 108010024284 Apolipoprotein C-II Proteins 0.000 abstract description 3
- 102100039998 Apolipoprotein C-II Human genes 0.000 abstract description 3
- 102100029470 Apolipoprotein E Human genes 0.000 abstract description 3
- 101710095339 Apolipoprotein E Proteins 0.000 abstract description 3
- 102000016918 Complement C3 Human genes 0.000 abstract description 3
- 108010028780 Complement C3 Proteins 0.000 abstract description 3
- 102000008946 Fibrinogen Human genes 0.000 abstract description 3
- 108010049003 Fibrinogen Proteins 0.000 abstract description 3
- 102000003886 Glycoproteins Human genes 0.000 abstract description 3
- 108090000288 Glycoproteins Proteins 0.000 abstract description 3
- 102000014702 Haptoglobin Human genes 0.000 abstract description 3
- 108050005077 Haptoglobin Proteins 0.000 abstract description 3
- 102100021519 Hemoglobin subunit beta Human genes 0.000 abstract description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 abstract description 3
- 102100039894 Hemoglobin subunit delta Human genes 0.000 abstract description 3
- 108091005903 Hemoglobin subunit delta Proteins 0.000 abstract description 3
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 abstract description 3
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 abstract description 3
- 101710089039 Ig gamma-2 chain C region Proteins 0.000 abstract description 3
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 abstract description 3
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 abstract description 3
- 108010071690 Prealbumin Proteins 0.000 abstract description 3
- 102000007584 Prealbumin Human genes 0.000 abstract description 3
- 108010071390 Serum Albumin Proteins 0.000 abstract description 3
- 102000007562 Serum Albumin Human genes 0.000 abstract description 3
- 102000004338 Transferrin Human genes 0.000 abstract description 3
- 108090000901 Transferrin Proteins 0.000 abstract description 3
- 229940060587 alpha e Drugs 0.000 abstract description 3
- 229940012952 fibrinogen Drugs 0.000 abstract description 3
- 108010044853 histidine-rich proteins Proteins 0.000 abstract description 3
- 102100033715 Apolipoprotein A-I Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 57
- 239000000499 gel Substances 0.000 description 40
- 238000001228 spectrum Methods 0.000 description 35
- 238000012360 testing method Methods 0.000 description 29
- 239000007983 Tris buffer Substances 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 13
- 102100021757 E3 ubiquitin-protein ligase RNF135 Human genes 0.000 description 11
- 101001106984 Homo sapiens E3 ubiquitin-protein ligase RNF135 Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 238000001295 Levene's test Methods 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- 241001248480 Alteromonadaceae Species 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000011551 log transformation method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CSGNYPOBLCWDIN-UHFFFAOYSA-N 2-aminoacetic acid prop-2-enamide Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.NC(=O)C=C CSGNYPOBLCWDIN-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- -1 Acryl Chemical group 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000131971 Bradyrhizobiaceae Species 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 101000834247 Danio rerio Actin, cytoplasmic 2 Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 101710158906 Ig alpha-1 chain C region Proteins 0.000 description 1
- 102100026217 Immunoglobulin heavy constant alpha 1 Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000989950 Otolemur crassicaudatus Hemoglobin subunit alpha-A Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800001442 Peptide pr Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 239000004355 Starch acetate esterified with vinyl acetate Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000001245 distarch phosphate Substances 0.000 description 1
- 235000013804 distarch phosphate Nutrition 0.000 description 1
- 238000007787 electrohydrodynamic spraying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000010544 human prion disease Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 239000001248 monostarch phosphate Substances 0.000 description 1
- 235000013807 monostarch phosphate Nutrition 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000001239 phosphated distarch phosphate Substances 0.000 description 1
- 235000013803 phosphated distarch phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019430 starch acetate esterified with vinyl acetate Nutrition 0.000 description 1
- 238000000551 statistical hypothesis test Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0426859.5A GB0426859D0 (en) | 2004-12-07 | 2004-12-07 | Diagnosis of neurodegenerative disorders |
| GB0426859.5 | 2004-12-07 | ||
| GBGB0521762.5A GB0521762D0 (en) | 2004-12-07 | 2005-10-25 | Diagnosis of neurodegenerative disorders |
| GB0521762.5 | 2005-10-25 | ||
| PCT/GB2005/004700 WO2006061610A2 (fr) | 2004-12-07 | 2005-12-07 | Diagnostic de maladies neurodégénératives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2590781A1 true CA2590781A1 (fr) | 2006-06-15 |
Family
ID=35695679
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002590775A Abandoned CA2590775A1 (fr) | 2004-12-07 | 2005-12-07 | Diagnostic de maladies neurodegeneratives |
| CA002590781A Abandoned CA2590781A1 (fr) | 2004-12-07 | 2005-12-07 | Diagnostic de maladies neurodegeneratives |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002590775A Abandoned CA2590775A1 (fr) | 2004-12-07 | 2005-12-07 | Diagnostic de maladies neurodegeneratives |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP1825274B1 (fr) |
| CA (2) | CA2590775A1 (fr) |
| WO (2) | WO2006061610A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2428240A (en) | 2005-07-14 | 2007-01-24 | Univ Gen Ve | Diagnostic method for brain damage-related disorders |
| GB0612192D0 (en) * | 2006-06-01 | 2006-08-02 | Electrophoretics Ltd | Diagnostic assay for spongiform encephalopathies |
| CA2712303C (fr) | 2008-01-18 | 2015-03-31 | President And Fellows Of Harvard College | Procedes de detection de signatures d'une maladie ou d'etats dans des fluides corporels |
| EP2596116A4 (fr) | 2010-07-23 | 2014-03-19 | Harvard College | Procédés de détection de maladies/pathologies auto-immunes ou liées au système immunitaire |
| BR112013001754A2 (pt) | 2010-07-23 | 2016-05-31 | Harvard College | método para detectar marcas de doença ou condições em fluídos corpóreos |
| CA2806304A1 (fr) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methodes de depistage de maladies ou d'affections prenatales ou liees a la grossesse |
| MX2013000917A (es) | 2010-07-23 | 2013-07-05 | Harvard College | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. |
| BR112014031414A2 (pt) | 2012-06-15 | 2017-06-27 | Stylli Harry | métodos de detectar doenças ou condições utilizando células doentes circulantes |
| KR20150035821A (ko) | 2012-06-15 | 2015-04-07 | 해리 스타일리 | 질환 또는 병태를 검출하는 방법 |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824988B2 (en) * | 2000-05-15 | 2004-11-30 | R.E.D. Laboratories, N.V. | Method and compositions for use in diagnosing and characterizing chronic immune disease |
| AU2003253883A1 (en) * | 2002-07-15 | 2004-02-02 | The Johns Hopkins University | Neuronal and optic nerve gene expression patterns |
-
2005
- 2005-12-07 EP EP05820667A patent/EP1825274B1/fr active Active
- 2005-12-07 CA CA002590775A patent/CA2590775A1/fr not_active Abandoned
- 2005-12-07 WO PCT/GB2005/004700 patent/WO2006061610A2/fr active Application Filing
- 2005-12-07 WO PCT/GB2005/004698 patent/WO2006061609A2/fr active Application Filing
- 2005-12-07 EP EP05823285A patent/EP1825275B1/fr active Active
- 2005-12-07 CA CA002590781A patent/CA2590781A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1825274B1 (fr) | 2009-11-18 |
| EP1825275B1 (fr) | 2010-06-16 |
| WO2006061610A2 (fr) | 2006-06-15 |
| WO2006061609A2 (fr) | 2006-06-15 |
| EP1825274A2 (fr) | 2007-08-29 |
| WO2006061610A3 (fr) | 2006-08-10 |
| WO2006061609A3 (fr) | 2006-09-08 |
| EP1825275A2 (fr) | 2007-08-29 |
| CA2590775A1 (fr) | 2006-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1825274B1 (fr) | Surveillance de la maladie de Huntington | |
| US8506957B2 (en) | Methods and compositions for monitoring progression of huntington's disease | |
| US11307208B2 (en) | Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers | |
| Holtta et al. | An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease | |
| JP6954839B2 (ja) | アルツハイマー病の診断及び治療のための材料及び方法 | |
| Zetterberg et al. | Clinical proteomics in neurodegenerative disorders | |
| Brechlin et al. | Cerebrospinal fluid‐optimized two‐dimensional difference gel electrophoresis (2‐D DIGE) facilitates the differential diagnosis of Creutzfeldt–Jakob disease | |
| Hanrieder et al. | Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates | |
| WO2010134308A1 (fr) | Biomarqueur pour troubles mentaux y compris les troubles cognitifs, et méthode de dépistage des troubles mentaux y compris des troubles cognitifs à l'aide dudit biomarqueur | |
| US20240175879A1 (en) | Method for assessing efficacy of treatment protocols for neurodegenerative diseases | |
| JP6113798B2 (ja) | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 | |
| EP3535587B1 (fr) | Procédés utilisant la spectrométrie de masse pour la détection de la circulation d'histones h3 et h2b dans le plasma de patients atteint de choc septique ou de sepsie | |
| Sohail et al. | Differential proteome analysis of diabetes mellitus type 2 and its pathophysiological complications | |
| US20110256169A1 (en) | Novel polypeptides related to b-type natriuretic peptides and methods of their identification and use | |
| JP6359158B2 (ja) | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 | |
| JP6359160B2 (ja) | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 | |
| JP6193942B2 (ja) | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 | |
| EP2638400A2 (fr) | Complexe de protéine/peptide lié à l'albumine en tant que biomarqueur pour une maladie | |
| KR20080091234A (ko) | 신장 질환의 진단 방법 및 이를 위한 마커 | |
| JP6359159B2 (ja) | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 | |
| WO2024051937A1 (fr) | Procédé d'évaluation de l'efficacité de protocoles de traitement pour des maladies neurodégénératives | |
| EP2021804B1 (fr) | Méthode de diagnostic d'encéphalopathies spongiformes | |
| Krishnamachari | Profiling cerebrospinal fluid proteins in Alzheimer's disease | |
| Hintzen | Marcel P. Stoop, Lennard J. Dekker, Mark K. Titulaer, Robert-Jan AN Lamers, Peter C. Burgers, Peter AE Sillevis Smitt, Alain J. van Gool, Theo M. Luider, and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20180116 |